The particle has landed--characterizing the fate of inhaled pharmaceuticals.
about
Inhaled nano- and microparticles for drug deliveryMetabolic Functions of the Lung, Disorders and Associated PathologiesIn Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory ApproachesInhaled Antibiotics for Gram-Negative Respiratory InfectionsTargeted Lung Delivery of Nasally Administered AerosolsTargeting aerosol deposition to and within the lung airways using excipient enhanced growthAerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery SystemsPEI-engineered respirable particles delivering a decoy oligonucleotide to NF-κB: inhibiting MUC2 expression in LPS-stimulated airway epithelial cellsTolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis PatientsA Role for Low Density Lipoprotein Receptor-Related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the LungsA Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition.Inhaled innate immune ligands to prevent pneumonia.Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airwayPharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.Nano-enabled delivery of diverse payloads across complex biological barriers.A new method for measuring lung deposition efficiency of airborne nanoparticles in a single breath.Inhaled antibiotics for gram-negative respiratory infections.Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.Pharmaceutical applications of the Calu-3 lung epithelia cell line.Mechanisms of absorption and elimination of drugs administered by inhalation.Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product.Nanoparticle-mediated pulmonary drug delivery: a reviewDry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure SystemDry powder inhalation: past, present and future.Materials and methods for delivery of biological drugs.The extracellular microenvironment explains variations in passive drug transport across different airway epithelial cell types.Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.Small Airway Absorption and Microdosimetry of Inhaled Corticosteroid Particles after Deposition.Pulmonary biodistribution and cellular uptake of intranasally administered monodisperse particles.Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.β2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility.The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis.Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines.Inducible Lung Epithelial Resistance Requires Multisource Reactive Oxygen Species Generation To Protect against Viral Infections.
P2860
Q26771328-3E347A37-69D4-451D-ADC9-46C843D39ECAQ28072037-94E557A9-FB52-4240-845D-9519891AD5C1Q28080832-82E342F6-2048-4532-9D76-19933D39EE98Q28386160-903844A7-7277-4A8F-B771-FA2620B579FEQ28387568-E7E03E07-2C0F-4FFE-89AB-26FF4085C8F9Q28390979-68DED9E8-A9D5-4382-8BD4-F801A0BAA762Q28392004-C031A86A-5B0D-4B96-9634-E5BB7909E734Q28484221-170B0F6F-F161-48E4-BE73-E70B3683F958Q28550641-0AFBB135-B9B4-4047-9D26-194F89137350Q28603536-7FD785D3-1403-4F1E-9F30-155692BCC9AAQ30313138-3BF11A78-ABC9-4F54-95D4-E7319AB9DAB8Q30398752-FFE8D5CC-8DF9-4C82-8B62-093D97CCBB67Q35563906-A0B147B1-8915-469D-8247-EBCCFCF4018EQ35768436-0CC8D716-7537-42CE-89DD-2FBC7AE30D10Q36307467-070F339D-E87D-4102-A2BE-E11D6E49FE0DQ37397186-CCEFCF6F-F0F9-4D4B-880B-3CB91456898EQ37937558-164D8AAC-2902-4350-B8CA-931CAD4F4DCBQ38088303-1714B9AA-C1F3-4D30-A5FB-14691C75C58CQ38111427-871E973E-22ED-4DCE-9C2A-5D9C7ED05375Q38126941-3941F5BF-6B56-4107-8D16-CEE675F637CFQ38185862-5CDEB56E-117E-4DE2-8A04-BCDD42486CAFQ38203377-E27E5617-A330-4EE7-A3B7-5311C7E4F887Q38690308-950D99D6-2713-4E2D-AD65-6DE996FD83ACQ38830375-3B000EEA-9FFE-4B47-B886-86DBFFD737E1Q38987392-DF5AF065-EC65-4F98-B55E-44AABD56CBC4Q39147212-C658837E-79D5-4FE1-941A-6695E6BF77A9Q39658347-EFC31F53-B558-4AA4-BE7A-CC54CB1BF0D7Q39848034-6FC86A74-1F81-49C0-817C-C6D0128C6B1CQ40121090-63CD0F49-2BDA-4343-AD44-3F38FD7DBD3AQ45061912-90EB94C6-61DD-41FB-A4D5-86A99C063C1FQ46571918-D03F16BD-354F-41A7-9185-9539F8165D6CQ47096485-D51B81AF-3401-4098-AF71-72990748B014Q47713313-0274A08F-E817-4320-B5FD-3FF4B831A495Q48096415-76E318AC-BD2E-445F-A814-FF13F600AACBQ48285552-63301D58-F025-4FC5-BE3B-77944DE457F3Q54210821-F9322A1E-8E28-45B9-945B-916D7347192E
P2860
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
@en
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
@nl
type
label
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
@en
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
@nl
prefLabel
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
@en
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
@nl
P2093
P356
P1476
The particle has landed--characterizing the fate of inhaled pharmaceuticals.
@en
P2093
Jennifer Fiegel
John S Patton
Joseph D Brain
Kwang-Jin Kim
Lee A Davies
Masahiro Sakagami
Rita Vanbever
P304
P356
10.1089/JAMP.2010.0836
P478
23 Suppl 2
P577
2010-12-01T00:00:00Z